Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study

Thrombosis Research

Volumn 135, Issue 5, 2015, Pages 852-860

  Douxfils, Jonathan ^a   Chatelain, Bernard ^a   Hjemdahl, Paul ^b   Devalet, Bérangère ^a   Sennesael, Anne Laure ^a   Wallemacq, Pierre ^c   Rönquist Nii, Yuko ^b   Pohanka, Anton ^b   Dogné, Jean Michel ^a   Mullier, François ^a  

^a University of Namur   (Belgium)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; DABIGATRAN; DABIGATRAN ETEXILATE; PHENPROCOUMON; RECOMBINANT THROMBOPLASTIN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DILUTE RUSSELL VIPER VENOM TIME TEST; DRUG BLOOD LEVEL; EMBOLISM; GENITAL BLEEDING; GINGIVA BLEEDING; HEART ATRIUM THROMBOSIS; HEMATOMA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIQUID CHROMATOGRAPHY; LUNG EMBOLISM; MINIMUM PLASMA CONCENTRATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; TANDEM MASS SPECTROMETRY; VEIN THROMBOSIS; ANTAGONISTS AND INHIBITORS; BLOOD; COMPARATIVE STUDY; DRUG MONITORING; MASS SPECTROMETRY; ORAL DRUG ADMINISTRATION; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THROMBOEMBOLISM; TIME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DABIGATRAN; DRUG MONITORING; HUMANS; INTERNATIONAL NORMALIZED RATIO; MASS SPECTROMETRY; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RETROSPECTIVE STUDIES; RIVAROXABAN; ROC CURVE; SENSITIVITY AND SPECIFICITY; THROMBOEMBOLISM; TIME FACTORS; VITAMIN K;

EID: 84928618395     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.02.020     Document Type: Article

References (29)

1. H. Ten Cate Monitoring new oral anticoagulants, managing thrombosis, or both? Thromb Haemost 107 2012 803 805
2. H. Ten Cate New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J 11 2013 8
3. H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke, and J. Oldgren European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651
4. J. Douxfils, F. Mullier, S. Robert, C. Chatelain, B. Chatelain, and J.M. Dogne Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate Thromb Haemost 107 2012 985 997
5. J.P. Antovic, M. Skeppholm, J. Eintrei, E.E. Boija, L. Soderblom, and E.M. Norberg Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma Eur J Clin Pharmacol 69 2013 1875 1881
6. J. Douxfils, F. Mullier, C. Loosen, C. Chatelain, B. Chatelain, and J.M. Dogne Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature Thromb Res 130 2012 956 966
7. J. Douxfils, J.M. Dogne, F. Mullier, B. Chatelain, Y. Ronquist-Nii, and R.E. Malmstrom Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate Thromb Haemost 110 2013 543 549
8. J. Douxfils, A. Tamigniau, B. Chatelain, C. Chatelain, P. Wallemacq, and J.M. Dogne Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban Thromb Haemost 110 2013 723 731
9. J. Douxfils, A. Tamigniau, B. Chatelain, C. Goffinet, J.M. Dogne, and F. Mullier Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays Thromb J 12 2014 24
10. G. Lippi, D. Ardissino, R. Quintavalla, and G. Cervellin Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests J Thromb Thrombolysis 38 2014 269 274
11. G.W. Moore Recent guidelines and recommendations for laboratory detection of lupus anticoagulants Semin Thromb Hemost 40 2014 163 171
12. T. Exner, L. Ellwood, J. Rubie, and A. Barancewicz Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study Thromb Haemost 109 2013 762 765
13. R. Altman, and C.D. Gonzalez Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs Thromb J 12 2014 7
14. G. Rohde Determination of rivaroxaban-a novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatography-tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 872 2008 43 50
15. Food and Drug Administration FDA Guidelines for Industry for Bioanalytical Method Validation 2001
16. J. Stangier, K. Rathgen, H. Stahle, D. Gansser, and W. Roth The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 2007 292 303
17. European Medicine Agency Validation of Analytical Procedures: Text and Methodology 1995
18. P.A. Reilly, T. Lehr, S. Haertter, S.J. Connolly, S. Yusuf, and J.W. Eikelboom The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) J Am Coll Cardiol 63 2014 321 328
19. European Medicines Agency Pradaxa - Summary of Product Characteristics 2014
20. J. Douxfils, S. Lessire, A.S. Dincq, P. Hjemdahl, Y. Ronquist-Nii, and A. Pohanka Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays Thromb Haemost 2014 113
21. D. Cohen Dabigatran: how the drug company withheld important analyses BMJ 349 2014 g4670
22. G. Pernod, P. Albaladejo, A. Godier, C.M. Samama, S. Susen, and Y. Gruel Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013 Arch Cardiovasc Dis 106 2013 382 393
23. G.M. van Os, B. de Laat, P.W. Kamphuisen, J.C. Meijers, and P.G. de Groot Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time J Thromb Haemost 9 2011 1657 1659
24. E. Merriman, Z. Kaplan, J. Butler, E. Malan, E. Gan, and H. Tran Rivaroxaban and false positive lupus anticoagulant testing Thromb Haemost 105 2011 385 386
25. M.M. Samama, J.L. Martinoli, L. LeFlem, C. Guinet, G. Plu-Bureau, and F. Depasse Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor Thromb Haemost 103 2010 815 825
26. B.R. Gudmundsdottir, C.W. Francis, A.M. Bjornsdottir, M. Nellbring, and P.T. Onundarson Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time Thromb Res 130 2012 674 681
27. W. Mueck, J. Stampfuss, D. Kubitza, and M. Becka Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban Clin Pharmacokinet 53 2014 1 16
28. A. Lillo-Le Louet, M. Wolf, L. Soufir, A. Galbois, A.S. Dumenil, and G. Offenstadt Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation Thromb Haemost 108 2012 583 585
29. A. Schattner, N. Kozak, and J. Friedman Fatality in a patient treated with dabigatran Am J Emerg Med 31 2013 443 e1-2